ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-kappa B Pathway in Human Non-Small Cell Lung Cancer

Song Libing*; Xiong Huaping; Li Jun; Liao Wenting; Wang Lan; Wu Jueheng; Li Mengfeng中山大学
Clinical Cancer Research2011-4-1DOI: 10.1158/1078-0432.CCR-10-0720
62被引4阅读
引用收藏
分享

摘要

Purpose: The present study was to examine the effect of sphingosine kinase-1 (SPHK1) on chemother-apeutics-induced apoptosis in non-small cell lung cancer (NSCLC) cells, which is relatively insensitive to chemotherapy, and its clinical significance in NSCLC progression. <br>Experimental Design: The correlation of SPHK1 expression and clinical features of NSCLC was analyzed in 218 paraffin-embedded archived NSCLC specimens by immunohistochemical analysis. The effect of SPHK1 on apoptosis induced by chemotherapeutics was examined both in vitro and in vivo, using Annexin V staining and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) assays. Western blotting and luciferase analysis were performed to examine the impact of SPHK1 on the PI3K/Akt /NF-kappa B signaling. <br>Results: The expression of SPHK1 was markedly increased in NSCLC and correlated with tumor progression and poor survival of patients with NSCLC. Upregulation of SPHK1 significantly inhibited doxorubicin-or docetaxel-induced apoptosis, associated with induction of antiapoptotic proteins Bcl-xl, cIAP1, c-IAP2, and TRAF1. In contrast, silencing SPHK1 expression or inhibiting SPHK1 activity with specific inhibitor, SK1-I, significantly enhanced the sensitivity of NSCLC cells to apoptosis induced by chemotherapeutics both in vitro and in vivo. Moreover, we demonstrated that upregulation of SPHK1 activated the PI3K/Akt/NF-kappa B pathway, and that inhibition of the PI3K/Akt/NF-kappa B pathway abrogated the antiapoptotic effect of SPHK1 on NSCLC cells. <br>Conclusions: Our results suggest that SPHK1 is a potential pharmacologic target for the treatment of NSCLC and inhibition of SPHK1 expression or its kinase activity might represent a novel strategy to sensitize NSCLC to chemotherapy. Clin Cancer Res; 17(7); 1839-49.

相关
加载中…
  • Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer
    Lin, Zhoujun; Li, Yin; Han, Xiao; Fu, Zhenkun; Tian, Zhenhuan*; Li, Chenggang*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23(21): 12741.被引 3
  • Sphingosine Kinase 1 Regulates the Akt/FOXO3a/Bim Pathway and Contributes to Apoptosis Resistance in Glioma Cells
    Guan Hongyu*; Song Libing; Cai Junchao; Huang Yongbo; Wu Jueheng; Yuan Jie; Li Jun; Li MengfengPLoS ONE, 2011, 6(5): e19946.被引 39
  • Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma
    Bao, Ji-Ming*; Zhi, Xi; Yuan, Hao-Yu; Chen, Tao-Yi; Chen, Ming-Kun; Zhou, Jun-Hao; Xue, Kang-Yi; Yang, Jian-Kun*; Liu, Cun-Dong*Translational Cancer Research, 2023, 12(3): 572-584.
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Cancer Research
发表日期
2011-04-01
卷期
第 17 卷, 第 7 期
页码
1839-1849
DOI
10.1158/1078-0432.CCR-10-0720
语言
ENGLISH
成果收录
SCI
资助标注
Natural Science Foundation of China [81071647, 81071762, 81071780, 81030048, 30770836, 30771110, 30870963, 30872930, 30831160517]; Program for New Century Excellent Talents in Universities [NCET-07-0877]; Science and Technology Department of Guangdong Province, China [8251008901000006, 2008A030201006]; Ministry of Education of China [(2008) 890, 200805580047]; Fundamental Research Funds for the Central Universities [10ykzd03]; China Central Government [2009ZX10004-213, 2009ZX09103-041]; Guangdong Recruitment Program of Creative Research Groups; [985-III]

作者

  • S

    Song Libing (通讯) (第一作者)

  • X

    Xiong Huaping

查看全部 7 位作者收起作者
  • L

    Li Jun

  • L

    Liao Wenting

  • W

    Wang Lan

  • W

    Wu Jueheng

  • L

    Li Mengfeng

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417